PatternsRadar
Sign in

ADVENZYMESAdvanced Enzyme Technologies Limited

NSE
Full chart
273.10INR+0.70 (+0.26%)Close · 6 Oct 2026
8 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹3,036 CrMarket cap
17.7P/E (TTM)
64.3%Delivery

Filings & corporate actions

43 results filed
CSV
Next results · Q2 FY27
Expected 2 Nov 2026 – 12 Nov 2026
Estimate: filed 33–43 days after quarter end, last 5 times
Dividend
₹1.35 per share · last 24 Jul 2026
2026
  • 8 AugresultsResults · Q1 FY27 · consolidated and standalone-9.2%NSE
  • 24 JuldividendDividend · ₹1.35 per share+1.0%
  • 18 JulshareholdingShareholding · 30 Jun 2026-0.5%NSE
  • 9 MayresultsResults · Q4 FY26 · consolidated and standalone+9.3%NSE
  • 14 AprshareholdingShareholding · 31 Mar 2026+0.9%NSE
  • 31 JanresultsResults · Q3 FY26 · consolidated and standalone-8.4%NSE
  • 16 JanshareholdingShareholding · 31 Dec 2025-2.1%NSE

Reaction to results · all yearsrose on day 0 in 19 of 41 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY278 Aug 2026-9.2%-5.8%-8.2%4.5×
Q4 FY269 May 2026+9.3%+1.8%+4.2%23.8×
Q3 FY2631 Jan 2026-8.4%-3.2%+1.2%1.5×
Q2 FY2612 Nov 2025+7.0%+6.1%-1.6%28.9×
Q1 FY262 Aug 2025-8.8%-16.8%-5.9%3.5×
Q4 FY2513 May 2025-0.8%+0.1%+15.2%1.9×
Q3 FY258 Feb 2025-2.5%-9.2%-16.7%1.3×
Q2 FY259 Nov 2024-15.3%-22.3%-19.8%6.4×
Q1 FY2510 Aug 2024-2.5%+10.7%+12.4%0.6×
Q4 FY2411 May 2024-2.9%-4.6%-8.5%1.2×
Q3 FY2410 Feb 2024+0.8%+7.0%-5.8%3.6×
Q2 FY247 Nov 2023+1.8%+0.6%+7.9%3.6×
Q1 FY2412 Aug 2023+1.4%0.0%-5.4%1.2×
Q4 FY2313 May 2023-1.8%-4.7%-5.6%8.6×
Q3 FY2311 Feb 2023-2.5%-2.6%-8.4%1.0×
Q2 FY2311 Nov 2022-1.7%-4.1%+9.5%0.6×
Q1 FY236 Aug 2022-4.7%-9.5%-5.9%1.4×
Q4 FY2220 May 2022-2.4%+4.3%-4.0%0.8×
Q3 FY225 Feb 2022-5.6%-10.8%-11.9%1.0×
Q2 FY222 Nov 2021-0.7%-3.3%-9.7%0.8×
Q1 FY227 Aug 2021+0.1%-6.8%-10.5%0.7×
Q4 FY2130 May 2021-6.4%-9.1%-10.1%1.0×
Q3 FY2112 Feb 2021+0.7%+5.8%-1.8%3.8×
Q2 FY2113 Nov 2020+2.6%+4.6%+8.1%1.8×
Q1 FY2112 Aug 2020-0.4%+12.5%+10.2%1.1×
Q4 FY2030 May 2020-0.1%+7.2%+15.7%1.1×
Q3 FY206 Feb 2020+0.3%-5.0%-21.5%1.2×
Q2 FY202 Nov 2019+0.8%-6.0%-12.8%4.2×
Q1 FY208 Aug 2019-1.8%-3.3%+4.7%0.8×
Q4 FY1924 May 2019+5.3%+6.6%-16.9%4.0×
Q3 FY1919 Feb 2019+0.2%-6.8%+11.6%0.9×
Q2 FY1923 Nov 2018-0.6%-2.4%-4.9%0.5×
Q1 FY1924 Aug 2018+0.1%+0.4%-7.0%0.4×
Q4 FY1826 May 2018+0.8%-2.6%+0.2%10.5×
Q3 FY1816 Mar 2018+3.9%-2.5%+4.9%2.0×
Q2 FY1820 Nov 2017+0.1%-0.1%+7.5%0.5×
Q1 FY1722 Sept 2017-3.0%-3.4%+1.8%1.0×
Q1 FY1822 Sept 2017-3.0%-3.4%+1.8%1.0×
Q4 FY1720 Jun 2017+0.1%-4.6%+3.8%0.7×
Q3 FY1721 Feb 2017+3.2%+5.5%+27.9%3.2×
Q2 FY1718 Nov 2016+0.9%+6.5%+11.6%0.4×
Average-1.1%-1.8%-1.0%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+2.1%
Profit YoY-4.6%
Interest cost YoY—
Revenue QoQ-6.7%
Profit QoQ-14.7%
CAGR2Y3Y4Y5Y6Y7Y
Revenue——————
Profit——————

Key data

CSV
Open273.40
Day range270.80 – 278.35
52-week range251.95 – 419.00
From 52w high-34.8%
RSI (14)28.8
ATR (14)8.30
Volume1.72L
Avg volume (20D)2.15L
Rel volume0.80×
Volatility (1Y)37.6%
Turnover₹4.7Cr
SMA 50 / 200299.20 / 312.51

Delivery percentage

Latest · 6 Oct 202664.3%
20-day avg57.6%
1-year avg53.9%
Percentile (own history)90th
Range8.3–95.5%
Sessions1,731

Over the last 20 sessions ADVENZYMES settled 57.6% of its traded quantity, which is above average for an NSE equity. Its one-year average is 53.9%, so recent sessions are running 3.7 points higher than usual. The latest session ranks higher than 90% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryBiotechnology
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+0.26%-3.55%-7.74%-14.67%+0.22%-14.66%

Valuation

CSV
Market cap₹3,036 Cr
P/E (TTM)17.7
EPS (TTM)15.45
Shares outstanding11.20Cr
Listed1 Aug 2016

Ownership

CSV
Promoter43.24%
Promoter Δ QoQ-0.02 pp
Public56.76%
FII26.71%
DII4.78%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)184.5171.9203.4189.8
YoY chg——+21.6%+2.1%
Net profit (₹ Cr)44.743.245.338.6
YoY chg——+69.3%-4.6%
Net margin24.2%25.1%22.3%20.3%
EPS3.873.793.843.31

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 43.24% · public 56.76%
30 Sept 2021: promoter 52.55%31 Dec 2021: promoter 52.71%31 Mar 2022: promoter 52.70%30 Jun 2022: promoter 52.70%30 Sept 2022: promoter 49.87%31 Dec 2022: promoter 49.87%31 Mar 2023: promoter 49.87%30 Jun 2023: promoter 46.52%30 Sept 2023: promoter 45.92%31 Dec 2023: promoter 43.62%31 Mar 2024: promoter 43.49%30 Jun 2024: promoter 43.02%30 Sept 2024: promoter 42.95%31 Dec 2024: promoter 42.93%31 Mar 2025: promoter 43.08%30 Jun 2025: promoter 43.08%30 Sept 2025: promoter 43.07%31 Dec 2025: promoter 43.04%31 Mar 2026: promoter 43.26%30 Jun 2026: promoter 43.24%
2021-092026-06
  • Promoter
  • Public and others
Promoter
43.24%
Public
56.76%
Promoter change
-0.02 pp
Filed
18 Jul 2026
FII
26.71%
DII
4.78%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations157.8160.9157.8154.5146.1169.1167.2185.9184.5171.9203.4189.8
Other income6.114.49.57.09.67.78.78.910.38.57.213.0
Total income163.9175.3167.3161.5155.7176.8175.9194.8194.8180.4210.6202.8
Total expenses116.0116.5112.6112.8113.5123.8132.5139.9135.3133.4150.9149.3
└ Finance costs0.80.70.80.90.90.90.80.80.70.60.60.6
└ Depreciation8.78.69.38.68.99.010.19.610.110.210.29.9
Profit before tax47.958.939.648.742.253.043.554.959.558.359.853.5
Tax expense12.716.49.713.78.814.116.714.514.815.114.614.9
Net profit35.242.529.935.033.438.926.740.444.743.245.338.6
EPS3.083.742.533.052.943.362.373.573.873.803.843.31
Net margin22.30%26.41%18.93%22.63%22.86%22.99%15.99%21.75%24.24%25.11%22.25%20.33%
PBT margin30.36%36.58%25.10%31.50%28.89%31.35%26.00%29.53%32.27%33.90%29.41%28.20%
Tax rate26.56%27.81%24.58%28.14%20.89%26.68%38.50%26.34%24.87%25.92%24.33%27.91%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 8 Aug 2026.

ADVENZYMES at a glance

  • ADVENZYMES closed at ₹273.1 on 6 Oct 2026, +0.26% on the day, -14.7% over one year, 34.8% below its 52-week high of ₹419.
  • Delivery was 64.3% of traded quantity on 6 Oct 2026, the 90th percentile of its own 1,731 sessions with a reading (20-session average 57.6%, 1-year average 53.9%).
  • Market capitalisation is ₹3,036 crore at a trailing P/E of 17.7 (trailing EPS ₹15.45).
  • Q1 FY27 results (consolidated, filed 8 Aug 2026): revenue ₹190 crore (+2.1% year on year), net profit ₹39 crore (-4.6%); the price moved -9.2% on the first session after.
  • Promoters held 43.24% at 30 Jun 2026, down 0.02 percentage points on the previous filing.
  • Q2 FY27 results are expected between 2 Nov 2026 and 12 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryBiotechnology
ISININE837H01020
SeriesEQ
Listed1 Aug 2016
History from1 Aug 2016
Sessions2,519

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE